PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that the required two-year animal carcinogenicity study for aclerastide has produced “clean results” related to safety findings and, in particular, carcinogenicity. This was the final study agreed to with the FDA for toxicological assessment.
Help employers find you! Check out all the jobs and post your resume.
